BEDFORD, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
Ocular to host webcast scheduled for Tuesday, February 17, 2026, at 8:00 AM ET Detailed SOL-1 data to be presented at the 49 th Macula Society Annual Meeting BEDFORD, Mass., Feb. 13, 2026 (GLOBE ...
BEDFORD, Mass., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today ...
Ocular Therapeutix targets retinal diseases, focusing on wet age-related macular degeneration (AMD) with its lead candidate, AXPAXLI (OTX-TKI). Current wet AMD treatment is dominated by anti-VEGF ...
From the laptops on your desk to satellites in space and AI that seems to be everywhere, I cover many topics at PCMag. I've covered PCs and technology products for over 15 years at PCMag and other ...
First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› Advice, staff picks, mythbusting, and more. Let us help you. Updated June 11, ...
You might be using an unsupported or outdated browser. To get the best possible experience please use the latest version of Chrome, Firefox, Safari, or Microsoft Edge ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
You might be using an unsupported or outdated browser. To get the best possible experience please use the latest version of Chrome, Firefox, Safari, or Microsoft Edge ...
Once you know what kind of trust you'd like, follow these steps to open a trust account. Many, or all, of the products featured on this page are from our advertising partners who compensate us when ...
Hosted on MSN
Ocular Therapeutix drug shows promise in eye disorder, but falls short of investor hopes
Ocular Therapeutix Inc. OCUL shares are down during Tuesday's premarket session following a significant announcement regarding their Axpaxli treatment for wet age-related macular degeneration (AMD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results